欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - a / indonesia / 05/2005 (h5n1) ako použitý kmeň (pr8-ibcdc-rg2) - influenza, human; immunization; disease outbreaks - vakcíny - aktívna imunizácia proti podtypu h5n1 vírusu chrípky-a. tento údaj je založený na immunogenicity údaje zo zdravých subjektov, od veku 18 rokov a ďalej po podaní lieku dve dávky vakcíny pripravené s podtypu h5n1 kmene. prepandrix by mali byť použité v súlade s oficiálne usmernenie.

欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

sanofi pasteur msd, snc - polyribosylribitol fosfát z hemofilovm influenzae typ b, ako prp-ompc, vonkajšia membrána proteínový komplex neisseria meningitidis (proteín vonkajšej membrány komplex b11 z kmeňov neisseria meningitidis podskupiny b), adsorbovanej hepatitídy b povrchových antigénov vyrobené v rekombinantnej kvasiniek (saccharomyces cerevisiae) - hepatitis b; meningitis, haemophilus; immunization - vakcíny - procomvax je indikovaný na očkovanie proti invazívnych ochorení spôsobených haemophilus influenzae typu b a infekcie spôsobené všetky známe podtypy vírusu hepatitídy b u dojčiat 6 týždňov až 15 mesiacov veku.

欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a.  - pandemic influenza vaccine (h5n1) (split virion, inaktivované, adjuvanted) - influenza, human; immunization; disease outbreaks - vakcíny - profylaxia chrípky v oficiálne deklarovanej pandemickej situácii. pandémia-chrípkové vakcíny by mali byť použité v súlade s oficiálne usmernenie.

欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - hepatitídy a vírus (neaktívne), hepatitída b povrchových antigénov - hepatitis b; hepatitis a; immunization - vakcíny - twinrix adult je indikovaný na použitie u neimunitných dospelých a dospievajúcich vo veku 16 rokov a starších, ktorí sú vystavení riziku infekcie hepatitídou a a hepatitídy b.

欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vakcíny - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. použitie tejto vakcíny by mali byť v súlade s oficiálne odporúčania.

欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - vakcíny - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. použitie tejto vakcíny by mali byť v súlade s oficiálne odporúčania.

欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - vakcíny - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. použitie tejto vakcíny by mali byť v súlade s oficiálne odporúčania.

欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

sanofi pasteur - sars-cov-2 prefusion spike delta tm protein, recombinant (b.1.351 strain) - covid-19 virus infection - vakcíny - vidprevtyn beta is indicated as a booster for active immunisation to prevent covid-19 in adults who have previously received an mrna or adenoviral vector covid-19 vaccine (see sections 4. 2 a 5. 1 in product information document). použitie tejto vakcíny by mali byť v súlade s oficiálne odporúčania.

欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

hipra human health s.l. - sars-cov-2 virus recombinant spike (s) protein receptor binding domain (rbd) fusion heterodimer – b.1.351-b.1.1.7 strains - covid-19 virus infection - vakcíny - bimervax is indicated as a booster for active immunisation to prevent covid-19 in individuals 16 years of age and older who have previously received a mrna covid-19 vaccine.

欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - infekcie syncytiálneho vírusu dýchacích ciest - vakcíny - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. pozri časti 4. 2 a 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. použitie tejto vakcíny by mali byť v súlade s oficiálne odporúčania.